{
    "id": 12862,
    "fullName": "FN1 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FN1-ALK results from the fusion of FN1 and ALK, demonstrating constitutive Alk phosphorylation, transformation in cultured cells, and tumor activity in mouse models (PMID: 22570254). FN1-ALK fusions have been identified in ovarian stromal sarcoma, inflammatory myofibroblastic tumor, and gastrointestinal leiomyomas (PMID: 22570254, PMID: 25682942, PMID: 27469327).",
            "references": [
                {
                    "id": 11131,
                    "pubMedId": 25682942,
                    "title": "FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25682942"
                },
                {
                    "id": 3705,
                    "pubMedId": 22570254,
                    "title": "Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22570254"
                },
                {
                    "id": 11132,
                    "pubMedId": 27469327,
                    "title": "Recurrent fusion of the genes FN1 and ALK in gastrointestinal leiomyomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469327"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2335,
        "geneSymbol": "FN1",
        "terms": [
            "FN1",
            "CIG",
            "ED-B",
            "FINC",
            "FN",
            "FNZ",
            "GFND",
            "GFND2",
            "LETS",
            "MSF",
            "SMDCF"
        ]
    },
    "variant": "FN1 - ALK",
    "createDate": "10/06/2015",
    "updateDate": "04/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15380,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited growth of transformed cells expressing FN1-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 13023,
                "profileName": "FN1 - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15379,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ensartinib (X-396) inhibited growth of transformed cells expressing FN1-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 13023,
                "profileName": "FN1 - ALK"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15378,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FN1-ALK demonstrated decreased response to Alecensa (alectinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 13023,
                "profileName": "FN1 - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4631,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FN1-ALK demonstrated sensitivity to Xalkori (crizotinib), resulting in tumor growth inhibition in cell line xenograft models (PMID: 22570254).",
            "molecularProfile": {
                "id": 13023,
                "profileName": "FN1 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3705,
                    "pubMedId": 22570254,
                    "title": "Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22570254"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4632,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells in mouse models expressing FN1-ALK demonstrated sensitivity to TAE684, resulting in inhibition of tumor growth in cell line xenograft models (PMID: 22570254).",
            "molecularProfile": {
                "id": 13023,
                "profileName": "FN1 - ALK"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3705,
                    "pubMedId": 22570254,
                    "title": "Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22570254"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13023,
            "profileName": "FN1 - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 7861,
                    "name": "ALK Inhibitor",
                    "profileName": "FN1 - ALK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}